Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
- The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
- Orphan Drug Designation granted in the US by the FDA ("US Food and Drug Administration") for laquinimod for the treatment of Huntington's disease
ANYARA
- A licensing agreement has been entered into with NeoTX Therapeutics Ltd
Tasquinimod, Paquinimod and SILC
- Out-licensing activities are continuing
- The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
- Product patent for SILC substances granted by the European Patent Office
New share issue
- Rights issue implemented in fourth quarter generating proceeds of SEK 53.7 M for the company after issue expenses
Financial summary
| SEK M | Oct - Dec | Jan - Dec | ||
| 2016 | 2015 | 2016 | 2015 | |
| Net sales | 7.1 | 5.0 | 19.0 | 16.3 |
| Operating loss | -13.5 | -28.2 | -55.1 | -177.9 |
| Loss for the period | -14.8 | -40.8 | -59.6 | -193.5 |
| Loss per share, before and after dilution (SEK) | -0.16 | -0.45 | -0.65 | -2.13 |
| Cash and cash equivalents | 77.7 | 103.6 | ||
- Operating costs for full-year 2016 reduced by 62% (SEK 120.1 M) compared with 2015
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0) 46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/b7db1773-1b32-4839-8243-826cdfe35a48
